Tech

Medical marijuana still being consumed, despite illegal status

A petition for the legalization of marijuana for medical purposes appeared on the Parliament's website in Ukraine. It had 25,000 votes for the consideration of legalization. On this basis, the Human Rights Committee has drafted a bill. Verkhovna Rada of Ukraine registered it back in May. A new study underscores the need for additional research on the effect of medical marijuana laws.

A petition for the legalization of marijuana for medical purposes appeared on the Parliament’s website in Ukraine. It had 25,000 votes for the consideration of legalization. On this basis, the Human Rights Committee has drafted a bill. Verkhovna Rada of Ukraine registered it back in May.

Bill No. 10313 provides four amendments to some legislative acts to ensure the fundamental right of a person to consume cannabis. Ulyana Suprun and a number of doctors support the legalization of medical cannabis.

Ukraine violators face criminal penalties

Meanwhile, in Ukraine for production, storage, transportation and, sale of marijuana, violators face administrative and criminal penalties. The term medical marijuana refers to using the whole, unprocessed marijuana plant or its basic extracts to treat symptoms of illness. The U.S. Food and Drug Administration has not recognized or approved the marijuana plant as medicine.

However, the scientific study of the chemicals in marijuana has led to two FDA-approved medications. That contain cannabinoid chemicals in pill form. Continued research may lead to more medications.

The marijuana plant contains chemicals that may help treat a range of illnesses and symptoms. Many people argue that it should be legal for medical purposes. In fact, a growing number of states have legalized marijuana for medical use.

Why marijuana is not an FDA-approved medicine

The FDA requires carefully conducted studies in hundreds to thousands of human subjects. This all is to determine the benefits and risks of a possible medication. Furthermore, they show that the benefits of the marijuana plant outweigh its risks in patients it’s meant to treat.

The scientific study of the chemicals in marijuana has led to two FDA-approved medications. (Source)

Medical Marijuana Laws and Prescription Opioid Use Outcomes

A new study underscores the need for additional research on the effect of medical marijuana laws. Early research suggested that there may be a relationship between the availability of medical marijuana and opioid analgesic overdose. In particular, a NIDA-funded study published medical cannabis laws. They experienced slower rates of increase in opioid analgesic overdose death rates compared to states without such laws.

A 2019 analysis re-examined this relationship using data through 2017.

Similar to the findings reported previously, this research team found that opioid overdose mortality rates between 1999-2010. Researchers found that the trend reversed with medical marijuana. Such states with medical cannabis laws experienced an overdose death rate of 22.7%.

This is higher than expected. The investigators uncovered no evidence that either broader cannabis laws. More restrictive laws associated with changes in opioid overdose mortality rates. These data, therefore, does not support the interpretation that access to cannabis reduces opioid overdose.

The authors note that neither study provides evidence of a causal relationship between marijuana access and opioid overdose deaths. Rather, they suggest that the associations are likely due to factors the researchers did not measure. However, they caution against drawing conclusions on an individual level from data. Research is still needed on the potential medical benefits of cannabis or cannabinoids.

(Featured Image by Robert Anasch)

First published in bbc a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

J. Frank Sigerson

J. Frank Sigerson is a business and financial journalist primarily covering crypto, cannabis, crowdfunding, technology, and marketing. He also writes about the movers and shakers in the stock market, especially in biotech, healthcare, mining, and blockchain. In the past, he has shared his thoughts on IT and design, social media, pop culture, food and wine, TV, film, and music. His works have been published in Investing.com, Equities.com, Seeking Alpha, Mogul, Small Cap Network, CNN, Technology.org, among others.

Recent Posts

Women Represent 61% of Home Cannabis Growers in the U.S.

A survey found that women comprise 61% of home cannabis growers, marking a diversion from…

8 hours ago

Denmark Proposes Making Its Medical Cannabis Program Permanent

Denmark plans to make its pilot medical cannabis program permanent following its success in treating…

1 day ago

Polish Lawmakers Petition Donald Tusk for Cannabis Decriminalization

Polish lawmakers have submitted a non-binding petition to Prime Minister Donald Tusk, urging cannabis decriminalization…

1 week ago

The UK Medical Cannabis Market: Growth, Diversification, and Opportunities

The UK medical cannabis market has rapidly grown since legalization in 2018, with private actors…

1 week ago

Alcohol & Cannabis: 60% of Cannabis Users Say It Helps Them Drink Less

A new study involving over 23,000 participants in New Zealand found that 60% of people…

1 week ago

French Interior and Justice Ministers Announce Measures to Combat Organized Crime

The French Ministers of the Interior and Justice announced a comprehensive plan to tackle organized…

2 weeks ago